Lunglife Ai Share Discussion Threads

[brummy_git] 02/4/2022 05:31

Justin Waite & I of Vox markets talked positively about LLAI y'day here (starts 21:50)

www.voxmarkets.co.uk/articles/stocks-to-follow-on-vox-markets-01-04-22-e84b46e/

www.youtube.com/watch?v=hnrHU3wl1l8&t=386s

[brummy_git] 28/3/2022 06:13

Steady as she goes at innovative, early-stage lung cancer diagnostics firm LungLife AI (re prelims).

Find out all the news & commentary here.

www.linkedin.com/posts/paul-hill-a5994116_llai-mrna-llai-activity-6914091559575531520-yiFP?utm_source=linkedin_share&;utm_medium=member_desktop_web

[brummy_git] 04/2/2022 16:17

Justin & I talk about Lunglife (starts 18:25) here in today's Stock Picking video.

www.youtube.com/watch?v=pT7NlRWpmC0&t=2s

[brummy_git] 02/2/2022 07:42

Another major IPO milestone achieved by pioneering lung cancer diagnostics firm LungLife AI .

All the news & commentary here.

www.linkedin.com/posts/paul-hill-a5994116_llai-activity-6894544988655742976-KkQo

[brummy_git] 26/11/2021 15:15

LLAI discussed here (42:15)

www.youtube.com/watch?v=4PCSEnaOMA8

[brummy_git] 19/11/2021 07:44

AI enabled & CTC based early-stage, lung cancer diagnostics firm LungLifeAI said today that it had been awarded accreditation by the College of American Pathologists (CAP).

Find out why this is important here.

www.linkedin.com/posts/paul-hill-a5994116_llai-llai-activity-6867365666555535360-0CXt

[red171] 17/9/2021 15:35

Where are shares sold? LLAI does not come up on a search of HL as one might expect

[brummy_git] 09/9/2021 06:20

Full steam ahead at LungLife, a developer of AI enabled medical diagnostics for detecting early stage lung cancer - via its patented, easy to use ‘circulating tumour cell’ blood test.

All the commentary here wrt H1 results today.

www.linkedin.com/posts/paul-hill-a5994116_llai-activity-6841614838112813057-hVxW

[gocanes] 19/7/2021 13:05

Investor presentation this Thursday @ 10am -

Matthew Walls, CEO and Paul Foulger, CFO will provide a live investor presentation via the Investor Meet Company platform at 10am BST on Thursday, 22 July 2021.



The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.



Investors can sign up to Investor Meet Company for free and add to meet GENinCode plc via:hxxps://www.investormeetcompany.com/genincode-plc/register-investor

[gocanes] 19/7/2021 13:04

Cardiovascular disease company, focused on clinically-proven genomic precision testing products, to seek admission to AIM through an IPO



GENinCode plc, the cardiovascular disease ("CVD") risk assessment company focused on predictive genetics for the prevention of cardiovascular disease, is delighted to announce its intention to seek admission of its issued and to be issued Ordinary Shares to trading on AIM, a market of the London Stock Exchange plc ("Admission"). On admission, the Company is expected to have a market capitalisation of approximately £42 million.

The Company's product portfolio draws on genomic precision testing using polygenic (multiple-genes) technology, advanced molecular testing, genotyping and sequencing. Through a simple blood or saliva sample, the Company can analyse a patient's medical information and genetic variants associated with CVD to determine a Genetic Risk Score which is used for the subsequent assessment of a patient's cardiovascular disease risk. The Company also provides risk assessment for thrombosis (genetic predisposition to blood clotting). The Company's SITAB system, a proprietary software, bioinformatics and algorithmic platform with online cloud-based reporting, is used to process and record test results and genetic information using algorithms and artificial intelligence to assess a patient's risk of a cardiovascular event. SITAB reports results directly via a web portal to healthcare practitioners, cardiologists and physicians, in a user-friendly format.



The current standard of care for primary prevention and assessment of the risk of CVD has been in use and largely unchanged for many years. It is based on risk assessment equations which evaluate 'classic' or 'traditional' cardiovascular risk factors such as age, gender, smoking, blood cholesterol levels and blood pressure among other factors for the onset of CVD. The equations enable physicians to categorise patients as being at low, moderate or high risk of a CVD event, usually over the subsequent 10-year period or sometimes using a 'lifetime' horizon from which the patient is then assessed for lifestyle changes or treatment.



It is recognised that these 'classic' or 'traditional' risk assessments are imperfect with events not infrequently occurring in those individuals categorised at 'low' or 'intermediate' risk. The advent of genetic risk assessment for CVD is now able to help identify and reclassify those individuals traditionally categorised in the 'low' or 'intermediate' risk populations who are at higher genetic risk of a CVD event than their current standard of care risk assessment suggests. This enables earlier in life preventative measures to be adopted to lower the future risk of a CVD event.



With CVD mortality levels continuing to rise globally, there is an increasing need for cardiologists to apply genetics to help advance patient prognosis and diagnosis to treat the onset of CVD. The Company's products combine predictive models of genetics and patient data using classic cardiovascular risk factors (CVRFs) and are designed to improve predictive capability and genetic risk assessment to provide a personalised and thereby tailored treatment pathway. Recent studies and scientific reports show the correlation between genetic load/burden and the onset of CVD. The Directors believe that GENinCode's technology is at the forefront of genetic risk assessment in the CVD space.


The Company's key products are CE-Marked with the core products Cardio inCode and Thrombo inCode having IP protection in the major growth markets of Europe, the UK and the United States. The Company has now commenced its commercial expansion programme in Europe, the UK and the United States.



On 28 April 2021, the Company announced a partnership to provide genetic testing from labs based at Royal Brompton and Harefield Hospitals. Following this, it was announced on 14 June 2021 that a product commercialisation agreement had been entered into with EVERSANA in the US. The Directors believe that the partnership with EVERSANA, a leading provider of global commercial services to the life science industry, will provide a significant opportunity for the Group to progress its commercialisation plans for the US.


The Company's commercialisation strategy in the US is a significant part of GENinCode's long-term growth and commercial strategy. The Directors expect Cardio inCode to be reviewed by the FDA as a De Novo device. The Company submitted an initial application to the FDA in February 2021 for Breakthrough Device designation for its Cardio inCode product. The FDA review is ongoing with a decision expected in Q3 2021.

[bertiebingo] 09/7/2021 14:11

I was only just listening, never heard of them so searched for a chat board... and here we are ! Gotta love stocks linked to Mount Sinai !

[brummy_git] 09/7/2021 06:47

Terrific insights here from Paul Pagano, CEO of LungLifeAI.

A next generation diagnostics firm that is aiming to launch its patented & world-class early stage lung cancer test in 2023.

www.linkedin.com/posts/paul-hill-a5994116_introduction-to-lunglife-ai-with-vox-markets-activity-6819154292482617344-oWRE